- Sourcews Report
- File
- HTML
- Size
- 24 Ko
- URL response
- 100%
- Source quality
- 100%
- Sourcews Explorer
Crucell Announces Research License Agreement with Bioceros on STARŪ Technology
20.05.08 - 08:05 ... source : Crucell
... Leiden, The Netherlands, 20 May 2008 - Dutch biopharma company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced a non-exclusive STARŪ research license agreement with Bioceros. The license agreement with the Netherlands based company Bioceros covers the production of monoclonal antibodies. Financial details of the agreement were not disclosed. About STARŪ Technology STARŪ technology is a production technology that is particularly useful for the production of recombinant human antibodies and proteins. It has a potentially broad application and is effective for production of antibodies and proteins on mammalian cell lines such as Crucell's PER.C6Ū human cell technology and the widely used Chinese hamster ovary (CHO) cell line. STARŪ technology contains genetic elements, called STARŪ elements, that enable stable and high-yield gene expression important to recombinant anti ...» Next (HTML)
Similar news
100% | 29.04.08 - 09:02 ... source : Crucell
... company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced a non-exclusive STARŪ research license agreement with Toyobo Gene Analysis Co. LTD. Under the agreement, Toyobo Gene Analysis will evaluate Crucell's STARŪ technology for generating cell lines for the ...
99% | 08.04.08 - 17:44 ... source : Crucell
... company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced a non-exclusive STARŪ research license agreement with Celltrion, Inc. for the production of recombinant proteins. Under the agreement, Celltrion will evaluate Crucell's STARŪ technology for generating cell lines for ...
99% | 25.03.08 - 17:21 ... source : Crucell
... Crucell N.V. today announced a non-exclusive STARŪ research license agreement with biopharmaceutical company Medarex for the production of monoclonal antibodies. Financial details of the agreement were not disclosed. About STARŪ Technology STARŪ technology is a production technology that is particularly ...
97% | 03.04.08 - 15:06 ... source : Crucell
... in new HIV vaccine Leiden, The Netherlands, 3 April 2008 - Dutch biotechnology company Crucell N.V. today announced that the novel recombinant adenovirus serotype 26 (rAd26) vector, which is jointly developed by Crucell and the Beth Israel Deaconess Medical Center ...
92% | 12.05.08 - 10:45 ... source : Jerini
... today the signing of a research collaboration agreement with Baxter AG to develop a novel synthetic molecule for use in affinity purification of a therapeutic protein. Under the terms of the agreement, Jerini will use its Peptides-to-Drugs (P2D) technology platform ...
